Milind Phadnis

Associate Professor

University of Kansas Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Statistics Statistics professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Milind Phadnis is an Associate Professor at the University of Kansas Medical Center in the United States. His research areas include clinical trials in oncology, statistical methodologies for time-to-event outcomes, and the impact of platelet transfusions on patient outcomes. Recent articles authored by him explore topics such as platelet transfusion reactions, dose comparison in metastatic breast cancer, and phase II trial designs utilizing Bayesian methods.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Jerry Ware

Professor

University of Arkansas for Medical Sciences

UNITED STATES

View details

X. Long Zheng

Professor and chair

University of Kansas Medical Center

UNITED STATES

View details

Shaima A. Alothman

SAUDI ARABIA

View details

Terry Harville

University of Arkansas for Medical Sciences

UNITED STATES

View details

S Susan Hedayati

Professor

University of Texas Southwestern Medical School

UNITED STATES

View details

jl Mehta

Distingusihed Professor

University of Arkansas System

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Milind Phadnis

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial

Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters

Group sequential design for time-to-event outcome with non-proportional hazards using the concept of relative time utilizing two different Weibull distributions

Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards

Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter

Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study

Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis

Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis

%PT-GSDesign: A SAS Macro for group sequential designs with time-to-event endpoint using the concept of proportional time

Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions

Using Cognitive Behavioral Therapy for Insomnia in People with Type 2 Diabetes, Pilot RCT Part I: Sleep and Concomitant Symptom

Some design considerations incorporating early futility for single‐arm clinical trials with time‐to‐event primary endpoints using Weibull distribution

Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time

Sleep Efficiency and Total Sleep Time in Individuals with Type 2 Diabetes with and without Insomnia Symptoms

Collaborators (6)

Jerry Ware

X. Long Zheng

Shaima A. Alothman

Terry Harville

S Susan Hedayati

jl Mehta

Make your next move.